Launched biosimilars Humira and Stelara in key markets ... biosphere development program in comparison with our peers. I have one more chart to discuss this addressing nearly $185,000,000,000 ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara® (ustekinumab) and Humira® (adalimumab), bringing the total ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

Since 2006, the European Union has approved 23 biosimilars, 16 of which are used in cancer; examples of recent approvals are CT-P10 and L01XC02, which are biosimilars of rituximab. 26 Worldwide, more ...

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.